A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pemetrexed; Sunitinib

Criteria

Inclusion Criteria:

• Patients with a diagnosis of a solid malignancy that is refractory to standard therapy or for which no standard therapy exists.

• Patients has a good performance status (ECOG 0 or 1)

Exclusion Criteria:

• Prior treatment with either pemetrexed or SU011248.

• Coughing up blood within 4 weeks before starting study treatment (small amounts okey).

• Hypertension that cannot be controlled by medications.